Sales within BioBusiness grew by 8% in LCY and by 6% in DKK. Sales of biopharmaceutical ingredients (BPI) experienced a positive development in 2009, while sales of microorganisms were flat. Within BPI, sales were positively affected by cell culture ingredients, Protein A, and plectasin. In the case of microorganisms, there was an increase in sales to the bioagricultural (BioAg) industry of more than 40% in LCY.
Sales of microorganisms were flat in LCY and increased by 2% in DKK. This was driven by better than expected sales in the BioAg segment, which grew by more than 40% in LCY. Our sustainable solutions allow farmers to use less fertilizer under certain conditions while still achieving at least the same crop yields. The industry is still in a relatively early development phase, and Novozymes sells primarily on the Canadian market.
Microorganism sales to both the institutional & household cleaning and the wastewater treatment segments declined due to the global recession and ongoing pruning activities.
In July 2009, the turf and landscape business was divested as part of the strategic focus on the core microorganism segments. The divestment had a negative effect on microorganism sales in 2009 of 4 percentage points.
Sales of BPI grew organically by 23% in LCY and by 13% in DKK. This strong growth was partly due to higher sales of cell culture ingredients and Protein A for our customers’ clinical trials, production, and purification of biopharmaceuticals. Furthermore, a milestone was achieved in the production and sales of the antimicrobial peptide plectasin.